Renal Denervation Devices Market by Technology, Products, Disease Application, End-User

Description

List of Tables

[192 Pages Report] The Renal Denervation Devices Market size was estimated at USD 236.29 million in 2023 and expected to reach USD 266.44 million in 2024, at a CAGR 13.68% to reach USD 579.85 million by 2030.

Renal denervation devices are medical tools that provide minimally invasive therapy for patients suffering from drug-resistant hypertension or high blood pressure that do not respond adequately to conventional pharmacological therapies. These devices offer an alternative solution by targeting the overactive sympathetic nerves surrounding the renal arteries, which play a crucial role in regulating blood pressure and contribute to the development of hypertension. The increasing prevalence of resistant hypertension among the global population due to lifestyle changes, rising awareness about the benefits of renal denervation procedures over conventional drug therapies, and the growing geriatric population are driving the renal denervation devices market growth. However, the high cost of renal denervation devices, associated procedures, and several stringent regulatory frameworks may hamper market growth. Technological advancements in device design and procedural techniques have improved efficacy and safety profiles for renal denervation treatments, which is expected to create a lucrative market opportunity.

KEY MARKET STATISTICS
Base Year [2023]	USD 236.29 million
Estimated Year [2024]	USD 266.44 million
Forecast Year [2030]	USD 579.85 million
CAGR (%)	13.68%

Technology: High adoption of ultrasound-based renal denervation technology

Micro-infusion-based renal denervation involves delivering small doses of anti-hypertensive drugs directly into the periarterial space surrounding the renal arteries. This targeted approach minimizes systemic side effects and improves drug efficacy. Pharmacologic ablation involves chemically destroying overactive renal nerves using neurotoxic agents such as alcohol or guanethidine. This technique is preferred when radiofrequency or ultrasound-based approaches are not feasible due to anatomical complexities or contraindications. Radiofrequency-based renal denervation involves applying controlled electrical energy to destroy targeted renal nerves. This method is preferred for its precision, safety, and effectiveness in reducing blood pressure. Ultrasound-based renal denervation uses high-frequency sound waves to generate localized heat that disrupts overactive renal nerves. This non-invasive technique makes it attractive for patients with contraindications or sensitivities to other methods.

Product: Significant use of multi-electrode catheters for their shorter-time of procedures

Catheters are the primary device used in renal denervation procedures to deliver radiofrequency energy to ablate or modify nerves responsible for hypertension. They are primarily used for their minimally invasive nature and precision in targeting specific nerves. Multi-electrode catheters have multiple electrodes on the tip that enable simultaneous ablation of multiple nerve sites, reducing procedure time and potentially increasing efficacy. Nerve-modifying agents are pharmaceuticals that work alongside renal denervation devices to enhance procedural outcomes. These agents may improve overall patient response or minimize potential complications arising from the procedure. An RF (Radiofrequency) generator is an essential device used in renal denervation procedures for providing controlled energy to catheters to ablate nerves. Single electrode catheters feature a single electrode at the tip and are used for sequential ablation of nerve sites. These catheters offer greater precision in targeting specific nerves but may require longer procedures than multi-electrode variants.

Disease Application: Proliferating use of renal denervation devices for treating hypertension

Renal denervation devices have emerged as an effective treatment for diabetic patients suffering from hypertension and nephropathy. These devices modulate the overactive sympathetic nervous system responsible for worsening diabetic complications. Heart failure patients experience high sympathetic activity, leading to increased blood pressure and fluid overload factors contributing to progressive kidney damage. Renal denervation therapy can effectively reduce sympathetic hyperactivity in these patients, improving cardiac function and overall quality of life. In hypertension, renal denervation helps lower blood pressure by disrupting the renal sympathetic nerves, reducing their influence on blood pressure regulation. Renal denervation devices are being explored as a potential treatment option for chronic kidney disease (CKD) patients who often suffer from hypertension and diabetic complications. The therapy's ability to modulate the sympathetic nervous system may help slow CKD progression and alleviate symptoms associated with kidney dysfunction.

End-User: Ambulatory care centers prioritize renal denervation devices as a minimally invasive and cost-effective solution

Ambulatory care centers (ACCs) are outpatient facilities that provide various medical services, including diagnosis and treatment for kidney-related diseases, and offer renal denervation devices to manage patients with hypertension. ACCs prefer minimally invasive and cost-effective solutions to ensure patient safety and comfort while maximizing operational efficiency. Diagnostic centers and hospitals are crucial in managing hypertension through early detection and intervention. With a growing global prevalence of uncontrolled hypertension and drug-resistant cases, these institutions require advanced renal denervation devices for optimal patient outcomes. Hospitals prioritize ease of use, adaptability with existing equipment, and robust clinical data support when selecting renal denervation devices. Research institutions and academic centers are at the forefront of hypertension management, developing novel therapies and devices for renal denervation. These organizations focus on cutting-edge technology with strong clinical evidence to support future advancements in the field.

Regional Insights

The Americas has a significant landscape in the renal denervation devices market due to a high prevalence of hypertension among its population and substantial investments in research for novel therapies. Advancements in technology and growing awareness about innovative treatment options amongst healthcare professionals have fueled demand for these devices. The EU shows significant potential for market growth owing to increased awareness about renal denervation therapy and favorable reimbursement policies across countries. Collaborative efforts on hypertension prevention and control have accelerated R&D initiatives in this domain. The MEA region holds promising opportunities for renal denervation devices due to a rising incidence of hypertension coupled with lifestyle changes and urbanization. In the APAC region, government funding and initiatives for hypertension research resulted in a growing number of clinical trials and patent filings. Robust healthcare infrastructure, a strong focus on technological advancements, increased awareness about hypertension management, and improved healthcare facilities have contributed to the region's renal denervation devices market growth.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Renal Denervation Devices Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Renal Denervation Devices Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Renal Denervation Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ablative Solutions, Inc., AngioDynamics, Inc., Aria CV, Inc., AtriCure, Inc., Bio-Heart, Boston Scientific Corporation, Cardinal Health, Inc., Kalos Medical, Medtronic PLC, Mercator MedSystems, Inc., Otsuka Holdings Co., Ltd., Shanghai Meiliweiye Medical Technology Co., Ltd., SoniVie, Symap Medical, Ltd., Symple Surgical, Inc., and Terumo Corporation.

Market Segmentation & Coverage

This research report categorizes the Renal Denervation Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Micro-Infusion-Based
- Pharmacologic Ablation
- Radiofrequency-Based
- Ultrasound-Based

Products
- Catheters
  - Multi Electrode Catheter
  - Single Electrode Catheter

Nerve Modifying Agents
RF Generator

Disease Application
- Diabetes
- Heart Failure
- Hypertension
- Renal Failure

End-User
- Ambulatory Care Centers
- Diagnostic Centers & Hospitals
- Research & Academia

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Renal Denervation Devices Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Renal Denervation Devices Market?

3. What are the technology trends and regulatory frameworks in the Renal Denervation Devices Market?

4. What is the market share of the leading vendors in the Renal Denervation Devices Market?

5. Which modes and strategic moves are suitable for entering the Renal Denervation Devices Market?

Product Code: MRR-957C47F91FC5

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of congestive chronic renal failure with aging population
  - 5.1.1.2. Growing adoption and inclination towards minimally invasive surgical procedures
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with renal denervation devices
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancements and improvements in renal denervation devices
  - 5.1.3.2. Ongoing publishing of clinical guidelines for renal denervation and increasing clinical assessment studies
- 5.1.4. Challenges
  - 5.1.4.1. Strict government regulations for product approval coupled with lack of experienced healthcare professionals
5.2. Market Segmentation Analysis
- 5.2.1. Technology: High adoption of ultrasound-based renal denervation technology
- 5.2.2. Product: Significant use of multi-electrode catheters for their shorter-time of procedures
- 5.2.3. Disease Application: Proliferating use of renal denervation devices for treating hypertension
- 5.2.4. End-User: Ambulatory care centers prioritize renal denervation devices as a minimally invasive and cost-effective solution
5.3. Market Trend Analysis
- 5.3.1. Favorable government approvals for renal denervation devices in the Americas backed by the presence of well-established medical device companies and rising medical professional acceptance
- 5.3.2. Expanding government support to improve diagnosis and treatment of hypertension coupled with increasing positive results from clinical trials of renal denervation devices in the APAC region
- 5.3.3. Supportive government initiatives and approval procedures for renal denervation devices across the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Renal Denervation Devices Market, by Technology

6.1. Introduction
6.2. Micro-Infusion-Based
6.3. Pharmacologic Ablation
6.4. Radiofrequency-Based
6.5. Ultrasound-Based

7. Renal Denervation Devices Market, by Products

7.1. Introduction
7.2. Catheters
7.3. Nerve Modifying Agents
7.4. RF Generator

8. Renal Denervation Devices Market, by Disease Application

8.1. Introduction
8.2. Diabetes
8.3. Heart Failure
8.4. Hypertension
8.5. Renal Failure

9. Renal Denervation Devices Market, by End-User

9.1. Introduction
9.2. Ambulatory Care Centers
9.3. Diagnostic Centers & Hospitals
9.4. Research & Academia

10. Americas Renal Denervation Devices Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Renal Denervation Devices Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Renal Denervation Devices Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
- 13.3.2. FDA Approves Verve Medical's IDE Renal Pelvic Denervation Trial
- 13.3.3. Korean Startup Kalos Gets USD 3.5 Million Grant to Develop Renal Denervation Device for hypertension Treatment
- 13.3.4. Renal Denervation Using Ultrasound Ablation in Treatment-Resistant Hypertension is Being Evaluated for Early Benefit Assessment in Germany
- 13.3.5. Andera Partners Invests in SoniVie, a Medtech Company Developing a Promising Device for the Treatment of Hypertension
- 13.3.6. Transitional Coverage for Renal Denervation Catheter SYMPLICITY SPYRAL from Medtronic in France
- 13.3.7. Shanghai Golden Leaf Med Tec Co., Ltd Secures Hundreds of Mns of CNY in Series C Round
- 13.3.8. SPYRAL HTN-ON MED Study Demonstrates Meaningful Clinical Benefits Consistent with other SPYRAL HTN Renal Denervation Trials
- 13.3.9. SoniVie Receives IDE Approval from FDA for its Pilot Study to Treat Hypertension with its Renal Artery Denervation TIVUS Technology
- 13.3.10. Ablative Solutions Raises USD 91.4 Million in Series D Financing Round
- 13.3.11. Clinical Accelerator Announces Collaboration with Verve Medical to Conduct an Early Human Feasibility Study for Treatment-Resistant Hypertension

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio